this journey alone.
and support for families facing FTD.
degeneration of the frontal
and/or temporal lobes of the brain.
What You Need to Know
that he has been diagnosed with FTD.
Statement
Statement
Resources
Action
4-5 p.m. EDT
provide a resource,
an outlet, and a place
to connect with others
who understand.
News & Events
AFTD Webinar: Sharing Your Story to Make a Difference — How to Connect with Legislators and Create Change
Cuts to federal programs are threatening the support systems that people living with FTD and their families rely on. Now more than ever, your voice matters. In this AFTD Advocacy…
MOREGuest Feature: Forget Me Not
The following Guest Feature was written by Jessica Powers, who is a care partner for her mother, Michelle. “Jessy, look what I planted for you. I know how much you…
MORELifestyle Changes Can Improve Cognition in Older Adults at Risk of Decline, Alzheimer’s Study Finds
Lifestyle changes, whether structured or self-guided, can improve cognition in older adults at risk of cognitive decline, according to the results of the Alzheimer’s Association’s US POINTER study. Structured Lifestyle…
MOREAFTD CEO Susan Dickinson to Retire in May 2026; AFTD Board Leading Search for Successor
When Susan L-J Dickinson was hired to lead AFTD, the organization had just two other part-time employees. Much of its day-to-day work was done by a small group of passionate…
MORETips & Advice: Brain Health and FTD
While no treatments have yet been approved for any type of FTD, emerging research is beginning to suggest that carriers of FTD-causing gene variants may be able to slow its…
MOREGenetic Counseling and Testing Should Be Offered to Persons Diagnosed with FTD, Experts Argue
A viewpoint article published in the medical journal Neurology argues that genetic counseling and testing should be offered to everyone diagnosed with FTD, underscoring the increasing number of trials for…
MORE“Alzheimer’s & Dementia” Summarizes Inaugural Holloway Summit’s Discussions on Digital Health Technologies for FTD
An article published in the journal Alzheimer’s & Dementia arose from AFTD’s inaugural Holloway Summit in 2022, which focused on digital health technologies (DHTs) and how they can help diagnose…
MOREPassage Bio Provides Updated Interim Data from UpliFT-D Clinical Trial for FTD-GRN
Biotechnology firm Passage Bio recently provided updated interim data from its phase 1/2 clinical trial for its gene replacement therapy targeting FTD-GRN. Experimental Therapy Continues to Show Improved Progranulin Levels…
MORE